Fosfomycin therapy of experimental infections in mice.
Fosfomycin inhibits the development of severe pyogenic infection by Staphylococcus aureus in kidneys if administered during establishment of infection. It inhibits the development of lethal infection by Escherichia coli. It has a positive therapeutic effect on listeria infection in mice even with a fosfomycin resistant mutant.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004927:Escherichia coli Infections / Q000517:prevention & control; D005578:Fosfomycin / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects; D008088:Listeriosis / Q000517:prevention & control; D051379:Mice; D009393:Nephritis / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D005578:Fosfomycin